Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
Robert J. Motzer
Consultant or Advisory Role - AVEO; Bayer; Genentech; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Expert Testimony - Pfizer
Brian I. Rini
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pfizer
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; GlaxoSmithKline; immatics; Merck; Millennium; Pfizer
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
Bruce G. Redman
No relevant relationships to disclose
Timothy Kuzel
Research Funding - Bristol-Myers Squibb
Michael Roger Harrison
Consultant or Advisory Role - AVEO; Exelixis; Novartis
Honoraria - Novartis; Prometheus
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer
Ulka N. Vaishampayan
No relevant relationships to disclose
Harry A. Drabkin
No relevant relationships to disclose
Saby George
Consultant or Advisory Role - Algeta/Bayer; Astellas Pharma; AVEO; Novartis; Sanofi
Research Funding - GlaxoSmithKline
Theodore F. Logan
No relevant relationships to disclose
Kim Allyson Margolin
No relevant relationships to disclose
Elizabeth R. Plimack
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Ian Waxman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Alexandre Lambert
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Hans J. Hammers
Research Funding - Bristol-Myers Squibb